A Prospective Approach to Inform and Treat 1340 Patients at Risk for BIA-ALCL

John M. Roberts, Logan W. Carr, Allison Jones, Amber Schilling, Donald R. Mackay, John Potochny

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: The increasing incidence and associated mortality of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has become alarming. However, many patients remain unaware of their risk for BIA-ALCL and may overlook early warning signs of the cancer. The authors aim to contact all breast implant patients at a single institution to educate them on the disease and provide screening and treatment as indicated. METHODS: All patients who had breast implants placed at Penn State Hershey Medical Center from 1979 to November of 2017 were mailed a letter to describe BIA-ALCL and to encourage a follow-up visit. Patient information regarding demographics, implant type, the number of calls and follow-up visits, physical examination findings, and patient decisions after being informed of the disease were recorded prospectively. RESULTS: One thousand two hundred eighty-four letters were mailed to 1020 patients (79.4 percent) with smooth implants and 264 patients (20.6 percent) with textured implants. Seventy-six calls were received and 100 patients (84 smooth and 16 textured) were evaluated within the first 2 months. Of the 16 patients with textured implants, nine are undergoing secondary surgery to remove or replace their textured device. CONCLUSIONS: Informing patients at risk for BIA-ALCL is an important endeavor. Patients educated on the disease will likely be diagnosed and treated earlier, which can prevent the need for adjuvant chemotherapy and/or radiation therapy and decrease mortality. The authors provide a method, supporting documents, and preliminary data to help other institutions contact their breast implant patients at risk for BIA-ALCL.

Original languageEnglish (US)
Pages (from-to)46-54
Number of pages9
JournalPlastic and reconstructive surgery
Volume144
Issue number1
DOIs
StatePublished - Jul 1 2019

Fingerprint

Anaplastic Large-Cell Lymphoma
Breast Implants
Mortality
Adjuvant Chemotherapy
Physical Examination

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Roberts, John M. ; Carr, Logan W. ; Jones, Allison ; Schilling, Amber ; Mackay, Donald R. ; Potochny, John. / A Prospective Approach to Inform and Treat 1340 Patients at Risk for BIA-ALCL. In: Plastic and reconstructive surgery. 2019 ; Vol. 144, No. 1. pp. 46-54.
@article{fd946321b92a41ae9b50a972cb2a9d4a,
title = "A Prospective Approach to Inform and Treat 1340 Patients at Risk for BIA-ALCL",
abstract = "BACKGROUND: The increasing incidence and associated mortality of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has become alarming. However, many patients remain unaware of their risk for BIA-ALCL and may overlook early warning signs of the cancer. The authors aim to contact all breast implant patients at a single institution to educate them on the disease and provide screening and treatment as indicated. METHODS: All patients who had breast implants placed at Penn State Hershey Medical Center from 1979 to November of 2017 were mailed a letter to describe BIA-ALCL and to encourage a follow-up visit. Patient information regarding demographics, implant type, the number of calls and follow-up visits, physical examination findings, and patient decisions after being informed of the disease were recorded prospectively. RESULTS: One thousand two hundred eighty-four letters were mailed to 1020 patients (79.4 percent) with smooth implants and 264 patients (20.6 percent) with textured implants. Seventy-six calls were received and 100 patients (84 smooth and 16 textured) were evaluated within the first 2 months. Of the 16 patients with textured implants, nine are undergoing secondary surgery to remove or replace their textured device. CONCLUSIONS: Informing patients at risk for BIA-ALCL is an important endeavor. Patients educated on the disease will likely be diagnosed and treated earlier, which can prevent the need for adjuvant chemotherapy and/or radiation therapy and decrease mortality. The authors provide a method, supporting documents, and preliminary data to help other institutions contact their breast implant patients at risk for BIA-ALCL.",
author = "Roberts, {John M.} and Carr, {Logan W.} and Allison Jones and Amber Schilling and Mackay, {Donald R.} and John Potochny",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/PRS.0000000000005703",
language = "English (US)",
volume = "144",
pages = "46--54",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

A Prospective Approach to Inform and Treat 1340 Patients at Risk for BIA-ALCL. / Roberts, John M.; Carr, Logan W.; Jones, Allison; Schilling, Amber; Mackay, Donald R.; Potochny, John.

In: Plastic and reconstructive surgery, Vol. 144, No. 1, 01.07.2019, p. 46-54.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Prospective Approach to Inform and Treat 1340 Patients at Risk for BIA-ALCL

AU - Roberts, John M.

AU - Carr, Logan W.

AU - Jones, Allison

AU - Schilling, Amber

AU - Mackay, Donald R.

AU - Potochny, John

PY - 2019/7/1

Y1 - 2019/7/1

N2 - BACKGROUND: The increasing incidence and associated mortality of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has become alarming. However, many patients remain unaware of their risk for BIA-ALCL and may overlook early warning signs of the cancer. The authors aim to contact all breast implant patients at a single institution to educate them on the disease and provide screening and treatment as indicated. METHODS: All patients who had breast implants placed at Penn State Hershey Medical Center from 1979 to November of 2017 were mailed a letter to describe BIA-ALCL and to encourage a follow-up visit. Patient information regarding demographics, implant type, the number of calls and follow-up visits, physical examination findings, and patient decisions after being informed of the disease were recorded prospectively. RESULTS: One thousand two hundred eighty-four letters were mailed to 1020 patients (79.4 percent) with smooth implants and 264 patients (20.6 percent) with textured implants. Seventy-six calls were received and 100 patients (84 smooth and 16 textured) were evaluated within the first 2 months. Of the 16 patients with textured implants, nine are undergoing secondary surgery to remove or replace their textured device. CONCLUSIONS: Informing patients at risk for BIA-ALCL is an important endeavor. Patients educated on the disease will likely be diagnosed and treated earlier, which can prevent the need for adjuvant chemotherapy and/or radiation therapy and decrease mortality. The authors provide a method, supporting documents, and preliminary data to help other institutions contact their breast implant patients at risk for BIA-ALCL.

AB - BACKGROUND: The increasing incidence and associated mortality of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has become alarming. However, many patients remain unaware of their risk for BIA-ALCL and may overlook early warning signs of the cancer. The authors aim to contact all breast implant patients at a single institution to educate them on the disease and provide screening and treatment as indicated. METHODS: All patients who had breast implants placed at Penn State Hershey Medical Center from 1979 to November of 2017 were mailed a letter to describe BIA-ALCL and to encourage a follow-up visit. Patient information regarding demographics, implant type, the number of calls and follow-up visits, physical examination findings, and patient decisions after being informed of the disease were recorded prospectively. RESULTS: One thousand two hundred eighty-four letters were mailed to 1020 patients (79.4 percent) with smooth implants and 264 patients (20.6 percent) with textured implants. Seventy-six calls were received and 100 patients (84 smooth and 16 textured) were evaluated within the first 2 months. Of the 16 patients with textured implants, nine are undergoing secondary surgery to remove or replace their textured device. CONCLUSIONS: Informing patients at risk for BIA-ALCL is an important endeavor. Patients educated on the disease will likely be diagnosed and treated earlier, which can prevent the need for adjuvant chemotherapy and/or radiation therapy and decrease mortality. The authors provide a method, supporting documents, and preliminary data to help other institutions contact their breast implant patients at risk for BIA-ALCL.

UR - http://www.scopus.com/inward/record.url?scp=85068974184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068974184&partnerID=8YFLogxK

U2 - 10.1097/PRS.0000000000005703

DO - 10.1097/PRS.0000000000005703

M3 - Article

C2 - 31246798

AN - SCOPUS:85068974184

VL - 144

SP - 46

EP - 54

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 1

ER -